Fig. 2: Comparison of the effects of the two oral analgesic treatments on clinical parameters in the cell-induced ALL models.
From: Improving pain management for murine orthotopic xenograft models of acute lymphoblastic leukemia
a,b, Probability of survival for the RS4;11 (a) and SEM (b) models after oral treatment with either metamizole (3 mg/ml) or tramadol (1 mg/ml) in the drinking water. c,d, Body weight change in the RS4;11 (c) and SEM (d) models. e,f, Distress score in the RS4;11 (e) and SEM (f) models. Body weight change and distress scores were quantified during the last regular assessment without analgesia (pre) and on the first days (1–5) with analgesic treatment of either metamizole or tramadol. g,h, Liquid intake the RS4;11 (g) and SEM (h) models. i,j, Perianal temperature in the RS4;11 (i) and SEM (j) models. k,l, MGS in the RS4;11 (k) and SEM (l) models. Liquid intake, perianal temperature and MGS were quantified at the late stage of ALL progression, without analgesia (pre) and on the first days (1–5) with analgesic intervention. Statistics (c–l): mixed-effects model with Šidák multiple-comparison test. Significant differences (P < 0.05) to pre shown for metamizole (‘a’) and tramadol (‘b’) are shown. Data are presented as box plots showing the 25th–75th percentiles, with minimum and maximum values. In addition, each data point represents an individual animal at a specific time point. Detailed information about statistical results is listed in Supplementary Table 2. RS4;11: metamizole n = 7 (3 males, 4 females); tramadol n = 7 (4 males, 3 females); SEM: metamizole n = 7 (3 males, 4 females), tramadol n = 6 (3 males, 3 females).
